Significant Unmet Needs
Fibralign is an award-winning, Stanford-spinout company that produces novel therapeutic biomedical devices that are designed to address major unmet medical needs.
The company has launched its first product, the BioBridge® Collagen Matrix, which has been developed to address secondary lymphedema*, a global chronic disease that currently has no cure.
BioBridge® Collagen Matrix
- Novel thread-like nanostructured surgical mesh for use in soft tissue repair
- Clinical benefit demonstrated in treating secondary lymphedema*
- CE mark approved, Class III device
- FDA 510(k) cleared device*
- Commercially available now in the US and Europe
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means to precisely print 3D scaffolding in such a way that mimics human tissue nano structure and directly influence the body’s repair function.
Grants, Awards, Partners and Collaborators
Fibralign has been recognized for its vision and potential to impact lives globally. We are supported in our mission by world class partners and collaborators.
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...
UChicago Medicine Enrolling Patients in Lymphbridge™ Clinical Study For Surgical Treatment Of Breast Cancer-Related Lymphedema
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment April 14, 2021 – The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge™, a randomized clinical study to evaluate a...
Multi-site clinical study to evaluate BioBridge® as prophylactic treatment for at-risk patients UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first...
* BioBridge has not been approved by the FDA for treating secondary lymphedema.